See C personal page - To The Moon

See C

No personal profile

1Follow

3Followers

0Topic

0Badge

2022-01-08

Wish so

3 COVID Stocks That Will Make Billions in 2022

2022-04-13

$TOP GLOVE CORPORATION BHD(BVA.SI)$Low price to buy

2022-09-19

[Smile]

5 High-Conviction Stocks to Buy in the Next Market Correction

2022-09-18

[Smile]

Upstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?

2022-01-07

Up And Down

Sorry, the original content has been removed

2022-04-17

$UNITED OVERSEAS BANK LIMITED(U11.SI)$Constantly growing

2022-01-13

Good job

AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US

2022-01-06

Amazing

Sony Jumped over 3% in Morning Trading as It Announced New Electric-Vehicle unit at CES 2022

2022-04-21

$SINGTEL(Z74.SI)$growing up

2022-04-20

$Tesla Motors(TSLA)$[Smile]

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4102833749708340","uuid":"4102833749708340","gmtCreate":1639734038607,"gmtModify":1639734038607,"name":"See C","pinyin":"seecseec","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":1,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9913398310,"gmtCreate":1663905578031,"gmtModify":1676537361093,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>","listText":"<a href=\"https://ttm.financial/S/Y92.SI\">$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$</a>","text":"$THAI BEVERAGE PUBLIC CO LTD(Y92.SI)$","images":[{"img":"https://community-static.tradeup.com/news/8fceec1e3f21ebcc675edde27c035669","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9913398310","isVote":1,"tweetType":1,"viewCount":2766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9913391720,"gmtCreate":1663905516160,"gmtModify":1676537361085,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/01810\">$XIAOMI-W(01810)$</a>","listText":"<a href=\"https://ttm.financial/S/01810\">$XIAOMI-W(01810)$</a>","text":"$XIAOMI-W(01810)$","images":[{"img":"https://community-static.tradeup.com/news/455c89f7d64bc97ad7ef248853a12ab2","width":"750","height":"1174"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9913391720","isVote":1,"tweetType":1,"viewCount":2486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9919682398,"gmtCreate":1663801006414,"gmtModify":1676537336976,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>","listText":"<a href=\"https://ttm.financial/S/C6L.SI\">$SINGAPORE AIRLINES LTD(C6L.SI)$</a>","text":"$SINGAPORE AIRLINES LTD(C6L.SI)$","images":[{"img":"https://community-static.tradeup.com/news/d24254b365ef448dbcac168a28d30232","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919682398","isVote":1,"tweetType":1,"viewCount":1930,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9919850998,"gmtCreate":1663775726514,"gmtModify":1676537334367,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>","listText":"<a href=\"https://ttm.financial/S/S68.SI\">$SINGAPORE EXCHANGE LIMITED(S68.SI)$</a>","text":"$SINGAPORE EXCHANGE LIMITED(S68.SI)$","images":[{"img":"https://community-static.tradeup.com/news/d03ae2caa25700a60e77e469325b15e7","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919850998","isVote":1,"tweetType":1,"viewCount":2867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9919065680,"gmtCreate":1663714368040,"gmtModify":1676537319203,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919065680","repostId":"1193461774","repostType":4,"repost":{"id":"1193461774","kind":"news","pubTimestamp":1663661566,"share":"https://ttm.financial/m/news/1193461774?lang=en_US&edition=fundamental","pubTime":"2022-09-20 16:12","market":"us","language":"en","title":"5 High-Conviction Stocks to Buy in the Next Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=1193461774","media":"Motley Fool","summary":"Here are five stocks you can confidently buy and hold the next time the market crashes.","content":"<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Conviction Stocks to Buy in the Next Market Correction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Conviction Stocks to Buy in the Next Market Correction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-20 16:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMG":"墨式烧烤","OKTA":"Okta Inc.","DOCU":"Docusign","SBUX":"星巴克","LULU":"lululemon athletica"},"source_url":"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193461774","content_text":"KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-term challenges to do well in the long run.It's useful to prepare a watchlist of stocks that you plan to accumulate. The markets are seeing heightened volatility in the past few months as the Federal Reserve hikes interest rates to tackle runaway inflation. With the NASDAQ Composite Index and S&P 500 already in a bear market this year, stock prices may have room to fall further. You should see a market correction as a golden opportunity to either accumulate more shares of companies you already own or to start a new position in a company that's become much cheaper.Of course, you'll need to ensure several attributes are in place before you pull the trigger. The business needs to demonstrate steady growth, be a dominant player within its industry, and enjoy tailwinds that will allow them to continue doing well. With these characteristics in place, a buy-and-hold strategy can ensure that you enjoy steady compounding to achieve your retirement goals.Here are five stocks you can consider buying during the next market correction.IMAGE SOURCE: GETTY IMAGES.StarbucksStarbucks is a global coffee chain with more than 34,000 stores around the world.  The company reported an encouraging set of earnings for its fiscal 2022's third quarter, with net revenue up 9% year over year to a record $8.2 billion. Comparable-store sales were up 3% globally, with the U.S. registering a 9% increase, and active Starbucks reward members climbed 13% year over year in the U.S. to 27.4 million members.During its recent biennial Investor Day, Starbucks unveiled an ambitious three-year financial roadmap to deliver annual comparable store sales growth of 7% to 9%, revenue growth of 10% to 12%, and earnings-per-share (EPS) growth of 15% to 20%. Founder and interim CEO Howard Shultz also introduced incoming CEO Laxman Narasimhan, who will assume his new role on April 1 next year. With this plan, it seems the company is kicking into high gear to deliver steady earnings growth for investors.LululemonLululemon is a market leader for athletic apparel and footwear for yoga, running, and training and provides innovative materials and interesting designs for its products. Results for its fiscal 2022's second quarter were impressive. Revenue increased 29% year over year to $1.9 billion, with comparable-store sales jumping 23% year over year. Net income surged by 39.1% year over year to $289.5 million, partially lifted by a $10.2 million one-off gain from the disposal of an administrative building.Lululemon has reported that supply chain woes are easing, allowing the company to manufacture the products it needs to satisfy strong demand. The sports apparel company expects net revenue to grow at a three-year compound annual growth rate of around 26% and for 2022 to register sales of between $7.87 billion to $7.94 billion.OktaOkta is a software-as-a-service business that offers identity management services to more than 16,400 customers to help their systems set up secure and convenient access. Okta's shares may have declined by nearly 72% year to date, but the company is still knocking the lights out with its latest Q2 2023 earnings. Revenue grew 43% year over year, with subscription revenue growing by 44% year over year. Subscription backlog improved by 25% year over year to 2.8 billion, while billings increased by 36% year over year.Okta believes there is a significant opportunity for it to continue growing as the total addressable market for its business is around $80 billion. The company has identified various growth drivers and will be implementing them to drive its top and bottom lines. It will work on improving its platform and network and also use its successful \"land and expand\" strategy in large organizations. International expansion is also on the cards as U.S. revenue made up more than three quarters of total revenue for the quarter.DocuSignIf you're looking for a quick, secure, and convenient way to digitally sign your business agreements, DocuSign has a cloud service that provides this service. The company boasts more than a billion users in 180 countries and also reported a solid  Q2 2023 report card. Subscription and total revenue continued climbing, up 23% and 22% year over year, respectively. Billings also saw an increase of 9% year over year.DocuSign believes that its Agreement Cloud has a large market opportunity with a total addressable market of around $50 billion. The company is confident in driving new use-cases such as the notarization of documents and analytics. By expanding on these new uses, DocuSign can drive greater adoption throughout the organization.Chipotle Mexican GrillChipotle Mexican Grill offers a wide menu of food items using responsibly sourced ingredients that do not contain artificial colors, flavors, or preservatives. The Mexican food chain, which boasts 3,000 restaurants in the U.S. and parts of Europe, reported continued growth in its Q2 2022 earnings report. Total revenue rose 17% year over year to $2.2 billion, with comparable-store sales up 10.1% year over year. Digital sales made up nearly 40% of revenue, showcasing the success with which Chipotle had achieved by pivoting to online orders during the pandemic.The company is pushing on with new store openings and expects to open between 235 and 250 new restaurants in 2022. The board of directors had also approved an additional $300 million to be used for share buybacks.","news_type":1,"symbols_score_info":{"DOCU":0.9,"CMG":0.9,"LULU":0.9,"SBUX":0.9,"OKTA":0.9}},"isVote":1,"tweetType":1,"viewCount":3257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910871247,"gmtCreate":1663602523490,"gmtModify":1676537299709,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910871247","repostId":"1158092150","repostType":4,"repost":{"id":"1158092150","kind":"news","pubTimestamp":1663596837,"share":"https://ttm.financial/m/news/1158092150?lang=en_US&edition=fundamental","pubTime":"2022-09-19 22:13","market":"us","language":"en","title":"Morgan Stanley, Goldman Sachs Warn of Mounting Risks for US Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1158092150","media":"Bloomberg","summary":"Higher rates and shrinking margins among key concernsGoldman likes companies with highest returns on","content":"<div>\n<p>Higher rates and shrinking margins among key concernsGoldman likes companies with highest returns on capitalAfter a hotter-than-expected inflation print and FedEx Corp.’s shocking profit warning, top ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-19/wall-street-strategists-see-pressure-building-for-us-earnings\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley, Goldman Sachs Warn of Mounting Risks for US Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley, Goldman Sachs Warn of Mounting Risks for US Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-19 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-19/wall-street-strategists-see-pressure-building-for-us-earnings><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Higher rates and shrinking margins among key concernsGoldman likes companies with highest returns on capitalAfter a hotter-than-expected inflation print and FedEx Corp.’s shocking profit warning, top ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-19/wall-street-strategists-see-pressure-building-for-us-earnings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-19/wall-street-strategists-see-pressure-building-for-us-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158092150","content_text":"Higher rates and shrinking margins among key concernsGoldman likes companies with highest returns on capitalAfter a hotter-than-expected inflation print and FedEx Corp.’s shocking profit warning, top Wall Street strategists see mounting risks for US earnings and equity valuations.Both Morgan Stanley’s Michael J. Wilson and Goldman Sachs Group Inc.’s David J. Kostin said headwinds to profitability are building, highlighting tighter monetary policy and pressure on company margins as key concerns. According to Wilson, who has been one of the most vocal bears on US stocks, “there is still a long way to go before reality is fairly priced.”While analysts’ estimates for US company earnings have been moderating recently, they are still near record highs -- despite a 19% slump for the S&P 500 benchmark this year. Revisions “are often glacial,” amid dependence on corporate guidance and due to the relatively defensive nature of the US index, Morgan Stanley’s Wilson wrote, warning of volatility ahead.The strategists’ comments come after a rough week for US stocks which saw the benchmark gauge drop 4.8% and the technology-heavy Nasdaq 100 post its worst week since January. Data showing consumer prices rose more than expected in August fueled fears about supersized Federal Reserve rate hikes, while FedEx’s warning was touted by some as the first of many to come from struggling companies.The “hot inflation print stoked concerns about the outlook for equity valuations and profitability,” said Goldman’s Kostin. His team expects S&P 500 net profit margins to fall 25 basis points in 2023, weighing further on returns on equity.The Goldman strategists said stocks with high returns on capital stand out in a backdrop of rising pressure on profitability and tighter financial conditions. They highlighted companies including Alphabet Inc., Domino’s Pizza Inc. and Philip Morris International Inc.Meanwhile, Wilson and his team “continue to recommend owning more defensively oriented companies with earnings stability and high operational efficiency.”Bank of America Corp. strategist Michael Hartnett echoed Morgan Stanley’s view last week, saying US equities haven’t yet seen the worst of this year’s declines amid scorching inflation and a hawkish Fed. Hartnett and his team expect an earnings recession to drive stocks to new lows.","news_type":1,"symbols_score_info":{".IXIC":0.9,".SPX":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":2570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910873422,"gmtCreate":1663602447367,"gmtModify":1676537299682,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9910873422","repostId":"1193461774","repostType":4,"repost":{"id":"1193461774","kind":"news","pubTimestamp":1663661566,"share":"https://ttm.financial/m/news/1193461774?lang=en_US&edition=fundamental","pubTime":"2022-09-20 16:12","market":"us","language":"en","title":"5 High-Conviction Stocks to Buy in the Next Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=1193461774","media":"Motley Fool","summary":"Here are five stocks you can confidently buy and hold the next time the market crashes.","content":"<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Conviction Stocks to Buy in the Next Market Correction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Conviction Stocks to Buy in the Next Market Correction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-20 16:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMG":"墨式烧烤","OKTA":"Okta Inc.","DOCU":"Docusign","SBUX":"星巴克","LULU":"lululemon athletica"},"source_url":"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193461774","content_text":"KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-term challenges to do well in the long run.It's useful to prepare a watchlist of stocks that you plan to accumulate. The markets are seeing heightened volatility in the past few months as the Federal Reserve hikes interest rates to tackle runaway inflation. With the NASDAQ Composite Index and S&P 500 already in a bear market this year, stock prices may have room to fall further. You should see a market correction as a golden opportunity to either accumulate more shares of companies you already own or to start a new position in a company that's become much cheaper.Of course, you'll need to ensure several attributes are in place before you pull the trigger. The business needs to demonstrate steady growth, be a dominant player within its industry, and enjoy tailwinds that will allow them to continue doing well. With these characteristics in place, a buy-and-hold strategy can ensure that you enjoy steady compounding to achieve your retirement goals.Here are five stocks you can consider buying during the next market correction.IMAGE SOURCE: GETTY IMAGES.StarbucksStarbucks is a global coffee chain with more than 34,000 stores around the world.  The company reported an encouraging set of earnings for its fiscal 2022's third quarter, with net revenue up 9% year over year to a record $8.2 billion. Comparable-store sales were up 3% globally, with the U.S. registering a 9% increase, and active Starbucks reward members climbed 13% year over year in the U.S. to 27.4 million members.During its recent biennial Investor Day, Starbucks unveiled an ambitious three-year financial roadmap to deliver annual comparable store sales growth of 7% to 9%, revenue growth of 10% to 12%, and earnings-per-share (EPS) growth of 15% to 20%. Founder and interim CEO Howard Shultz also introduced incoming CEO Laxman Narasimhan, who will assume his new role on April 1 next year. With this plan, it seems the company is kicking into high gear to deliver steady earnings growth for investors.LululemonLululemon is a market leader for athletic apparel and footwear for yoga, running, and training and provides innovative materials and interesting designs for its products. Results for its fiscal 2022's second quarter were impressive. Revenue increased 29% year over year to $1.9 billion, with comparable-store sales jumping 23% year over year. Net income surged by 39.1% year over year to $289.5 million, partially lifted by a $10.2 million one-off gain from the disposal of an administrative building.Lululemon has reported that supply chain woes are easing, allowing the company to manufacture the products it needs to satisfy strong demand. The sports apparel company expects net revenue to grow at a three-year compound annual growth rate of around 26% and for 2022 to register sales of between $7.87 billion to $7.94 billion.OktaOkta is a software-as-a-service business that offers identity management services to more than 16,400 customers to help their systems set up secure and convenient access. Okta's shares may have declined by nearly 72% year to date, but the company is still knocking the lights out with its latest Q2 2023 earnings. Revenue grew 43% year over year, with subscription revenue growing by 44% year over year. Subscription backlog improved by 25% year over year to 2.8 billion, while billings increased by 36% year over year.Okta believes there is a significant opportunity for it to continue growing as the total addressable market for its business is around $80 billion. The company has identified various growth drivers and will be implementing them to drive its top and bottom lines. It will work on improving its platform and network and also use its successful \"land and expand\" strategy in large organizations. International expansion is also on the cards as U.S. revenue made up more than three quarters of total revenue for the quarter.DocuSignIf you're looking for a quick, secure, and convenient way to digitally sign your business agreements, DocuSign has a cloud service that provides this service. The company boasts more than a billion users in 180 countries and also reported a solid  Q2 2023 report card. Subscription and total revenue continued climbing, up 23% and 22% year over year, respectively. Billings also saw an increase of 9% year over year.DocuSign believes that its Agreement Cloud has a large market opportunity with a total addressable market of around $50 billion. The company is confident in driving new use-cases such as the notarization of documents and analytics. By expanding on these new uses, DocuSign can drive greater adoption throughout the organization.Chipotle Mexican GrillChipotle Mexican Grill offers a wide menu of food items using responsibly sourced ingredients that do not contain artificial colors, flavors, or preservatives. The Mexican food chain, which boasts 3,000 restaurants in the U.S. and parts of Europe, reported continued growth in its Q2 2022 earnings report. Total revenue rose 17% year over year to $2.2 billion, with comparable-store sales up 10.1% year over year. Digital sales made up nearly 40% of revenue, showcasing the success with which Chipotle had achieved by pivoting to online orders during the pandemic.The company is pushing on with new store openings and expects to open between 235 and 250 new restaurants in 2022. The board of directors had also approved an additional $300 million to be used for share buybacks.","news_type":1,"symbols_score_info":{"DOCU":0.9,"CMG":0.9,"LULU":0.9,"SBUX":0.9,"OKTA":0.9}},"isVote":1,"tweetType":1,"viewCount":4218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9937767648,"gmtCreate":1663509685784,"gmtModify":1676537281116,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9937767648","repostId":"1118505487","repostType":4,"repost":{"id":"1118505487","kind":"news","pubTimestamp":1663463528,"share":"https://ttm.financial/m/news/1118505487?lang=en_US&edition=fundamental","pubTime":"2022-09-18 09:12","market":"us","language":"en","title":"Upstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?","url":"https://stock-news.laohu8.com/highlight/detail?id=1118505487","media":"TipRanks","summary":"Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from","content":"<div>\n<p>Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect\">Source Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-18 09:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc.","AFRM":"Affirm Holdings, Inc."},"source_url":"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118505487","content_text":"Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the current environment somewhat better, while its profitability prospects offer a wider margin of safety. For reasons mentioned below, I believe Upstart stock has a much higher chance of recovering compared to Affirm.Upstart (NASDAQ: UPST) and Affirm (NASDAQ: AFRM) were two of the most sought-after IPOs in late 2020 and early 2021. The two companies saw their shares surge during the first few months of trading in the public markets. Yet, Upstart & Affirm are currently trading around 94% and 87% off their all-time highs – quite a staggering development.In this article, I am going to provide some context on what caused such massive declines following the IPO euphoria of 2020 and 2021 and then speculate which one of the two names has the higher chance of making investors’ money back.What Caused Upstart & Affirm to Surge Only to Violently Decline After?The IPO market went nuts last year, and for a good reason. With investors riding the euphoria formed by the post-COVID-19 recovery, trillions of dollars flooding the market following government assistance to businesses and individuals, and monetary easing encouraging cheap borrowing, inflated valuations persisted strongly. Thus, it was probably the best time in history to take your company public, as investment banks, VC funds, and angel investors could exit their holdings at fantastic multiples.To add some color to the picture, in 2019 and 2020, 232 and 480 IPOs were completed. In fact, 480 was a new record at the time. In 2021, this number skyrocketed to an unprecedented 1,035, more than two times higher than the previous year’s record. Then, reality knocked on investors’ doors.Who would have thought that printing over $5 trillion dollars would cause inflation levels to surge? Some did, and inflation certainly did surge. In fact, it remains at sky-high levels. Then, things took a contrasting turn. With the FED eager to control inflation via rising interest rates, the economy has been set to slow down.Add growing costs amid supply-chain constraints and a tight labor market, and the previously sky-high valuation multiples were no longer justifiable by any means possible. It’s no wonder that during the first nine months of 2022, only 153 IPOs have taken place – a fraction compared to last year.The majority of the companies that went public amid last year’s euphoria would never make enough money any time soon to justify their stock prices, hence why many of these stocks declined by 80% to 90% from their all-time highs in the span of a few months. Upstart and Affirm were met with the same fate. In fact, these companies were affected massively due to their business model requiring a thriving economy to produce growing results.Which Stock Has the Chance to Make Your Money Back?As just mentioned, Upstart and Affirm, in particular, require blossoming economic conditions to grow since the former’s business model is focused on lending and the latter’s on buy-now-pay-later (BNPL). As you can easily imagine, nobody is going to borrow money or buy products that they may not be able to repay later. Thus, the two businesses have a hard time in a rising-rate environment loaded with uncertainty.However, if I had to bet which stock has the higher chance of coming back from the dead, it would definitely be Upstart. This is due to its lean, margin-rich business model, which should start building equity value on the balance sheet quite rapidly. For context, Upstart’s gross and EBITDA margins over the past four quarters amount to 83.7% and 9.7%, respectively. In the case of Affirm, these figures stand at 49% and -53%.Source: Koyfin.comClearly, Upstart’s current and future profitability prospects are levels ahead of Affirm’s. Most certainly, investors are unlikely to prefer a money-losing business in the current environment. This is because raising additional funds these days would be disastrous. Investors would be massively diluted for the extra cash at the stock’s current price levels.Upstart’s business model has the upper hand here, as even though lending volumes may decline, the company continues to license its AI platform to banks, which results in high-margin, recurring cash flows. In fact, while lending activities may shrink, banks actually need Upstart’s AI more than ever to filter between creditworthy and uncreditworthy borrowers in the current environment.Affirm loses here, as merchants aren’t encouraged to use its platform if they think the current economic conditions will prevent customers from paying back their commitments.From a margin of safety point of view, Upstart stock also has the upper hand. The company is currently trading at around 19.6x Fiscal 2023’s expected earnings, which is quite an attractive valuation multiple considering that it could grow notably from there if economic conditions improve. Again, making money these days is truly important.Further, due to Upstart management recognizing the fact that shares are cheap against the company’s future profit prospects, earlier this year, they announced a $400 million repurchase program. No repurchases have taken place yet, though the program makes for a good reminder that the company is profitable and will be returning capital to shareholders.In contrast, Affirm is not expected to make any money, at least all the way through Fiscal 2025, if not for longer. Thus, investors have little to no margin of safety in comparison, with the company’s equity value likely to go down the drain during this time.Conclusion: Upstart Looks Like the Better ChoiceBetween Upstart’s AI-lending and Affirm’s BNPL business models, the former has a clear advantage during the ongoing macroeconomic landscape. Additionally, Upstart profitability prospects are much more attractive, providing investors with a much wider margin of safety against Affirm’s money-losing operations. This, combined with the fact that Upstart is trading at a relatively cheap valuation, leads me to the conclusion that Upstart has a significantly higher chance of repairing investors’ recent losses.","news_type":1,"symbols_score_info":{"AFRM":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":3267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9937651111,"gmtCreate":1663427745633,"gmtModify":1676537269251,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9937651111","repostId":"1153896735","repostType":4,"repost":{"id":"1153896735","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1663337307,"share":"https://ttm.financial/m/news/1153896735?lang=en_US&edition=fundamental","pubTime":"2022-09-16 22:08","market":"us","language":"en","title":"Hot Chinese ADRs Slipped in Morning Trading with Pinduoduo Sliding Over 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153896735","media":"Tiger Newspress","summary":"Hot Chinese ADRs slipped in morning trading with Pinduoduo sliding over 5%.","content":"<html><head></head><body><p>Hot Chinese ADRs slipped in morning trading with Pinduoduo sliding over 5%.<img src=\"https://static.tigerbbs.com/4d62c1b0f96f499826c918a61b0e5054\" tg-width=\"435\" tg-height=\"604\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot Chinese ADRs Slipped in Morning Trading with Pinduoduo Sliding Over 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot Chinese ADRs Slipped in Morning Trading with Pinduoduo Sliding Over 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-09-16 22:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Hot Chinese ADRs slipped in morning trading with Pinduoduo sliding over 5%.<img src=\"https://static.tigerbbs.com/4d62c1b0f96f499826c918a61b0e5054\" tg-width=\"435\" tg-height=\"604\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多","JD":"京东","BABA":"阿里巴巴"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153896735","content_text":"Hot Chinese ADRs slipped in morning trading with Pinduoduo sliding over 5%.","news_type":1,"symbols_score_info":{"JD":0.9,"PDD":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":2343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9906602019,"gmtCreate":1659529568533,"gmtModify":1705981277568,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>potential","listText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>potential","text":"$Moderna, Inc.(MRNA)$potential","images":[{"img":"https://community-static.tradeup.com/news/0e625e7ffe340d305b5d7e4de9fb0425","width":"750","height":"2009"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906602019","isVote":1,"tweetType":1,"viewCount":3405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9040199853,"gmtCreate":1655616114472,"gmtModify":1676535672712,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9040199853","repostId":"9022524674","repostType":1,"repost":{"id":9022524674,"gmtCreate":1653552819200,"gmtModify":1676535303082,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"Time Travel with Tiger, Join the Memorabilia Adventure Now!!!","htmlText":"\n \n \n  Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi\n \n","listText":"Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi","text":"Happy Birthday to TIGER!!! This year, we have prepared a time machine to go on an adventure with you. Come and find surprising gifts as we stroll down memory lane!There are so many wonderful little stories in our Tiger Quest. Collect as many coins as you can in the game, these will be your basic points of this game. Apart from one mini-game mission for SG/AU/NZ, the games will be open every week, and there are endless treasures waiting for you to discover. Points can be redeemed for multiple rewards, and you can win a share of up to USD 200,000 worth of prizes! Want to win extra points? Check out these mini-games, try them, stay with us and be PAWSITIVE!Remember to collect the cards and spell out \"T.I.G.E.R\" during your journey for a chance to receive the limited edition 8th Anniversary Gi","images":[],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022524674","isVote":1,"tweetType":2,"object":{"id":"97af7069aa6440eab7c85601f72b41b1","tweetId":"9022524674","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/5836ee3f387702302012189230/1IRQdazMc4YA.mp4","poster":"https://community-static.tradeup.com/news/f2462b20b2a9a2483ae56cbb54dcb2a7"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":930,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9082857202,"gmtCreate":1650552691704,"gmtModify":1676534750569,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Z74.SI\">$SINGTEL(Z74.SI)$</a>growing up","listText":"<a href=\"https://ttm.financial/S/Z74.SI\">$SINGTEL(Z74.SI)$</a>growing up","text":"$SINGTEL(Z74.SI)$growing up","images":[{"img":"https://community-static.tradeup.com/news/7f6801acc4a43057043daef49fbf2c06","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9082857202","isVote":1,"tweetType":1,"viewCount":976,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9086531245,"gmtCreate":1650468228080,"gmtModify":1676534731255,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>[Smile]&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>[Smile]&nbsp;","text":"$Tesla Motors(TSLA)$[Smile]","images":[{"img":"https://community-static.tradeup.com/news/ba6796632a0cf47e20f88403e6a2d7ca","width":"750","height":"2059"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9086531245","isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9088038308,"gmtCreate":1650289115776,"gmtModify":1676534687369,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Will go up&nbsp;","listText":"Will go up&nbsp;","text":"Will go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088038308","repostId":"9081864000","repostType":1,"repost":{"id":9081864000,"gmtCreate":1650235566039,"gmtModify":1676534672697,"author":{"id":"3586127272341946","authorId":"3586127272341946","name":"StickyRice","avatar":"https://community-static.tradeup.com/news/93860c945685006c561393099fa7ee30","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586127272341946","idStr":"3586127272341946"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/EPR\">$EPR Properties(EPR)$</a>Yeah&nbsp;","listText":"<a href=\"https://ttm.financial/S/EPR\">$EPR Properties(EPR)$</a>Yeah&nbsp;","text":"$EPR Properties(EPR)$Yeah","images":[{"img":"https://community-static.tradeup.com/news/0d4cce943d92248a7a9ba6c994e6e70a","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081864000","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081952501,"gmtCreate":1650185506346,"gmtModify":1676534665579,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/U11.SI\">$UNITED OVERSEAS BANK LIMITED(U11.SI)$</a>Constantly growing&nbsp;","listText":"<a href=\"https://ttm.financial/S/U11.SI\">$UNITED OVERSEAS BANK LIMITED(U11.SI)$</a>Constantly growing&nbsp;","text":"$UNITED OVERSEAS BANK LIMITED(U11.SI)$Constantly growing","images":[{"img":"https://community-static.tradeup.com/news/4f7bf6de7196a630be684eb64495b2bc","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081952501","isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9089460250,"gmtCreate":1650022856882,"gmtModify":1676534630691,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089460250","repostId":"9016476123","repostType":1,"repost":{"id":9016476123,"gmtCreate":1649229403658,"gmtModify":1676534474180,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"🏆【GAME】Hunting Eggs for Extra Saving!","htmlText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","listText":"Tiger has prepared some Easter gifts for you, please&nbsp;<a href=\"https://www.tigerbrokers.com.sg/activity/market/2022/easter/\" target=\"_blank\">click&nbsp;here</a>&nbsp;to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","text":"Tiger has prepared some Easter gifts for you, please click here to check them out!Easter can still be a bonus-boosting. Come and find the eggs in our Easter game to open the surprise! Each game contains 3 rounds, the more eggs you catch, the higher the points you can get. Game points can be redeemed for various rewards, including different value stock vouchers worth up to USD 1,000 are waiting for you! Moreover, catching special eggs can get extra points and chances to crack open for some wonderful Easter treats.There are too many hidden surprises to find, oops, the game attempts run out too fast. Don't worry, complete different tasks to earn more game attempts. Also, invite your frien","images":[{"img":"https://community-static.tradeup.com/news/15b435c0d10e0e89ad3e06b7bbd04830","width":"2251","height":"1334"},{"img":"https://community-static.tradeup.com/news/ff9640a9df2f24446e07b7a9b658cb4b","width":"1200","height":"630"},{"img":"https://community-static.tradeup.com/news/795038848b7c7b1d7dda27d92b580946","width":"1656","height":"948"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016476123","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9080208036,"gmtCreate":1649891408448,"gmtModify":1676534597906,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>growing","listText":"<a href=\"https://ttm.financial/S/OV8.SI\">$SHENG SIONG GROUP LTD(OV8.SI)$</a>growing","text":"$SHENG SIONG GROUP LTD(OV8.SI)$growing","images":[{"img":"https://community-static.tradeup.com/news/41626050fa72628c6a689a59db99ae42","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080208036","isVote":1,"tweetType":1,"viewCount":1157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9080068399,"gmtCreate":1649819681146,"gmtModify":1676534583871,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>Low price to buy","listText":"<a href=\"https://ttm.financial/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>Low price to buy","text":"$TOP GLOVE CORPORATION BHD(BVA.SI)$Low price to buy","images":[{"img":"https://community-static.tradeup.com/news/a4318a0be03541597d6c9d80c92be720","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080068399","isVote":1,"tweetType":1,"viewCount":1356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9002451911,"gmtCreate":1642079273764,"gmtModify":1676533678536,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002451911","repostId":"1109527672","repostType":4,"repost":{"id":"1109527672","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642076396,"share":"https://ttm.financial/m/news/1109527672?lang=en_US&edition=fundamental","pubTime":"2022-01-13 20:19","market":"us","language":"en","title":"AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US","url":"https://stock-news.laohu8.com/highlight/detail?id=1109527672","media":"Benzinga","summary":"AstraZeneca Plc said the U.S. government has agreed to purchase an additional 500,000 doses of its a","content":"<html><head></head><body><p><b>AstraZeneca Plc</b> said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.</p><ul><li>The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.</li><li>The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.</li><li>In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.</li><li>The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.</li><li>The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.</li><li><b>Price Action:</b> AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-13 20:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>AstraZeneca Plc</b> said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.</p><ul><li>The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.</li><li>The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.</li><li>In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.</li><li>The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.</li><li>The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.</li><li><b>Price Action:</b> AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109527672","content_text":"AstraZeneca Plc said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.Price Action: AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.","news_type":1,"symbols_score_info":{"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006373547,"gmtCreate":1641618688112,"gmtModify":1676533635371,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Wish so","listText":"Wish so","text":"Wish so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006373547","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=en_US&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","VIR":"Vir Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"VIR":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9006373547,"gmtCreate":1641618688112,"gmtModify":1676533635371,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Wish so","listText":"Wish so","text":"Wish so","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006373547","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://ttm.financial/m/news/1134509683?lang=en_US&edition=fundamental","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<html><head></head><body><p>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><b>A safe harbor in stormy weather</b></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><b>The antibody market all to itself</b></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","VIR":"Vir Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"VIR":0.9,"PFE":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9080068399,"gmtCreate":1649819681146,"gmtModify":1676534583871,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>Low price to buy","listText":"<a href=\"https://ttm.financial/S/BVA.SI\">$TOP GLOVE CORPORATION BHD(BVA.SI)$</a>Low price to buy","text":"$TOP GLOVE CORPORATION BHD(BVA.SI)$Low price to buy","images":[{"img":"https://community-static.tradeup.com/news/a4318a0be03541597d6c9d80c92be720","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9080068399","isVote":1,"tweetType":1,"viewCount":1356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9910873422,"gmtCreate":1663602447367,"gmtModify":1676537299682,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9910873422","repostId":"1193461774","repostType":4,"repost":{"id":"1193461774","kind":"news","pubTimestamp":1663661566,"share":"https://ttm.financial/m/news/1193461774?lang=en_US&edition=fundamental","pubTime":"2022-09-20 16:12","market":"us","language":"en","title":"5 High-Conviction Stocks to Buy in the Next Market Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=1193461774","media":"Motley Fool","summary":"Here are five stocks you can confidently buy and hold the next time the market crashes.","content":"<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Conviction Stocks to Buy in the Next Market Correction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Conviction Stocks to Buy in the Next Market Correction\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-20 16:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMG":"墨式烧烤","OKTA":"Okta Inc.","DOCU":"Docusign","SBUX":"星巴克","LULU":"lululemon athletica"},"source_url":"https://www.fool.com/investing/2022/09/19/5-high-conviction-stocks-to-buy-in-the-next-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193461774","content_text":"KEY POINTSThese companies have strong market positions in their respective industries.They continue to demonstrate healthy growth during tough times.Their resilience allows them to get through short-term challenges to do well in the long run.It's useful to prepare a watchlist of stocks that you plan to accumulate. The markets are seeing heightened volatility in the past few months as the Federal Reserve hikes interest rates to tackle runaway inflation. With the NASDAQ Composite Index and S&P 500 already in a bear market this year, stock prices may have room to fall further. You should see a market correction as a golden opportunity to either accumulate more shares of companies you already own or to start a new position in a company that's become much cheaper.Of course, you'll need to ensure several attributes are in place before you pull the trigger. The business needs to demonstrate steady growth, be a dominant player within its industry, and enjoy tailwinds that will allow them to continue doing well. With these characteristics in place, a buy-and-hold strategy can ensure that you enjoy steady compounding to achieve your retirement goals.Here are five stocks you can consider buying during the next market correction.IMAGE SOURCE: GETTY IMAGES.StarbucksStarbucks is a global coffee chain with more than 34,000 stores around the world.  The company reported an encouraging set of earnings for its fiscal 2022's third quarter, with net revenue up 9% year over year to a record $8.2 billion. Comparable-store sales were up 3% globally, with the U.S. registering a 9% increase, and active Starbucks reward members climbed 13% year over year in the U.S. to 27.4 million members.During its recent biennial Investor Day, Starbucks unveiled an ambitious three-year financial roadmap to deliver annual comparable store sales growth of 7% to 9%, revenue growth of 10% to 12%, and earnings-per-share (EPS) growth of 15% to 20%. Founder and interim CEO Howard Shultz also introduced incoming CEO Laxman Narasimhan, who will assume his new role on April 1 next year. With this plan, it seems the company is kicking into high gear to deliver steady earnings growth for investors.LululemonLululemon is a market leader for athletic apparel and footwear for yoga, running, and training and provides innovative materials and interesting designs for its products. Results for its fiscal 2022's second quarter were impressive. Revenue increased 29% year over year to $1.9 billion, with comparable-store sales jumping 23% year over year. Net income surged by 39.1% year over year to $289.5 million, partially lifted by a $10.2 million one-off gain from the disposal of an administrative building.Lululemon has reported that supply chain woes are easing, allowing the company to manufacture the products it needs to satisfy strong demand. The sports apparel company expects net revenue to grow at a three-year compound annual growth rate of around 26% and for 2022 to register sales of between $7.87 billion to $7.94 billion.OktaOkta is a software-as-a-service business that offers identity management services to more than 16,400 customers to help their systems set up secure and convenient access. Okta's shares may have declined by nearly 72% year to date, but the company is still knocking the lights out with its latest Q2 2023 earnings. Revenue grew 43% year over year, with subscription revenue growing by 44% year over year. Subscription backlog improved by 25% year over year to 2.8 billion, while billings increased by 36% year over year.Okta believes there is a significant opportunity for it to continue growing as the total addressable market for its business is around $80 billion. The company has identified various growth drivers and will be implementing them to drive its top and bottom lines. It will work on improving its platform and network and also use its successful \"land and expand\" strategy in large organizations. International expansion is also on the cards as U.S. revenue made up more than three quarters of total revenue for the quarter.DocuSignIf you're looking for a quick, secure, and convenient way to digitally sign your business agreements, DocuSign has a cloud service that provides this service. The company boasts more than a billion users in 180 countries and also reported a solid  Q2 2023 report card. Subscription and total revenue continued climbing, up 23% and 22% year over year, respectively. Billings also saw an increase of 9% year over year.DocuSign believes that its Agreement Cloud has a large market opportunity with a total addressable market of around $50 billion. The company is confident in driving new use-cases such as the notarization of documents and analytics. By expanding on these new uses, DocuSign can drive greater adoption throughout the organization.Chipotle Mexican GrillChipotle Mexican Grill offers a wide menu of food items using responsibly sourced ingredients that do not contain artificial colors, flavors, or preservatives. The Mexican food chain, which boasts 3,000 restaurants in the U.S. and parts of Europe, reported continued growth in its Q2 2022 earnings report. Total revenue rose 17% year over year to $2.2 billion, with comparable-store sales up 10.1% year over year. Digital sales made up nearly 40% of revenue, showcasing the success with which Chipotle had achieved by pivoting to online orders during the pandemic.The company is pushing on with new store openings and expects to open between 235 and 250 new restaurants in 2022. The board of directors had also approved an additional $300 million to be used for share buybacks.","news_type":1,"symbols_score_info":{"DOCU":0.9,"CMG":0.9,"LULU":0.9,"SBUX":0.9,"OKTA":0.9}},"isVote":1,"tweetType":1,"viewCount":4218,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9937767648,"gmtCreate":1663509685784,"gmtModify":1676537281116,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9937767648","repostId":"1118505487","repostType":4,"repost":{"id":"1118505487","kind":"news","pubTimestamp":1663463528,"share":"https://ttm.financial/m/news/1118505487?lang=en_US&edition=fundamental","pubTime":"2022-09-18 09:12","market":"us","language":"en","title":"Upstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?","url":"https://stock-news.laohu8.com/highlight/detail?id=1118505487","media":"TipRanks","summary":"Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from","content":"<div>\n<p>Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect\">Source Link</a>\n\n</div>\n","source":"lsy1606183248679","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstart vs. Affirm: Which Beaten-Down IPO is Most Likely to Resurrect?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-18 09:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the ...</p>\n\n<a href=\"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc.","AFRM":"Affirm Holdings, Inc."},"source_url":"https://www.tipranks.com/news/article/upstart-vs-affirm-which-beaten-down-ipo-is-most-likely-to-resurrect","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118505487","content_text":"Story HighlightsFollowing last year’s IPO craze, numerous equities have suffered massive losses from their past highs, including shares of Upstart & Affirm. Upstart’s business model matches the current environment somewhat better, while its profitability prospects offer a wider margin of safety. For reasons mentioned below, I believe Upstart stock has a much higher chance of recovering compared to Affirm.Upstart (NASDAQ: UPST) and Affirm (NASDAQ: AFRM) were two of the most sought-after IPOs in late 2020 and early 2021. The two companies saw their shares surge during the first few months of trading in the public markets. Yet, Upstart & Affirm are currently trading around 94% and 87% off their all-time highs – quite a staggering development.In this article, I am going to provide some context on what caused such massive declines following the IPO euphoria of 2020 and 2021 and then speculate which one of the two names has the higher chance of making investors’ money back.What Caused Upstart & Affirm to Surge Only to Violently Decline After?The IPO market went nuts last year, and for a good reason. With investors riding the euphoria formed by the post-COVID-19 recovery, trillions of dollars flooding the market following government assistance to businesses and individuals, and monetary easing encouraging cheap borrowing, inflated valuations persisted strongly. Thus, it was probably the best time in history to take your company public, as investment banks, VC funds, and angel investors could exit their holdings at fantastic multiples.To add some color to the picture, in 2019 and 2020, 232 and 480 IPOs were completed. In fact, 480 was a new record at the time. In 2021, this number skyrocketed to an unprecedented 1,035, more than two times higher than the previous year’s record. Then, reality knocked on investors’ doors.Who would have thought that printing over $5 trillion dollars would cause inflation levels to surge? Some did, and inflation certainly did surge. In fact, it remains at sky-high levels. Then, things took a contrasting turn. With the FED eager to control inflation via rising interest rates, the economy has been set to slow down.Add growing costs amid supply-chain constraints and a tight labor market, and the previously sky-high valuation multiples were no longer justifiable by any means possible. It’s no wonder that during the first nine months of 2022, only 153 IPOs have taken place – a fraction compared to last year.The majority of the companies that went public amid last year’s euphoria would never make enough money any time soon to justify their stock prices, hence why many of these stocks declined by 80% to 90% from their all-time highs in the span of a few months. Upstart and Affirm were met with the same fate. In fact, these companies were affected massively due to their business model requiring a thriving economy to produce growing results.Which Stock Has the Chance to Make Your Money Back?As just mentioned, Upstart and Affirm, in particular, require blossoming economic conditions to grow since the former’s business model is focused on lending and the latter’s on buy-now-pay-later (BNPL). As you can easily imagine, nobody is going to borrow money or buy products that they may not be able to repay later. Thus, the two businesses have a hard time in a rising-rate environment loaded with uncertainty.However, if I had to bet which stock has the higher chance of coming back from the dead, it would definitely be Upstart. This is due to its lean, margin-rich business model, which should start building equity value on the balance sheet quite rapidly. For context, Upstart’s gross and EBITDA margins over the past four quarters amount to 83.7% and 9.7%, respectively. In the case of Affirm, these figures stand at 49% and -53%.Source: Koyfin.comClearly, Upstart’s current and future profitability prospects are levels ahead of Affirm’s. Most certainly, investors are unlikely to prefer a money-losing business in the current environment. This is because raising additional funds these days would be disastrous. Investors would be massively diluted for the extra cash at the stock’s current price levels.Upstart’s business model has the upper hand here, as even though lending volumes may decline, the company continues to license its AI platform to banks, which results in high-margin, recurring cash flows. In fact, while lending activities may shrink, banks actually need Upstart’s AI more than ever to filter between creditworthy and uncreditworthy borrowers in the current environment.Affirm loses here, as merchants aren’t encouraged to use its platform if they think the current economic conditions will prevent customers from paying back their commitments.From a margin of safety point of view, Upstart stock also has the upper hand. The company is currently trading at around 19.6x Fiscal 2023’s expected earnings, which is quite an attractive valuation multiple considering that it could grow notably from there if economic conditions improve. Again, making money these days is truly important.Further, due to Upstart management recognizing the fact that shares are cheap against the company’s future profit prospects, earlier this year, they announced a $400 million repurchase program. No repurchases have taken place yet, though the program makes for a good reminder that the company is profitable and will be returning capital to shareholders.In contrast, Affirm is not expected to make any money, at least all the way through Fiscal 2025, if not for longer. Thus, investors have little to no margin of safety in comparison, with the company’s equity value likely to go down the drain during this time.Conclusion: Upstart Looks Like the Better ChoiceBetween Upstart’s AI-lending and Affirm’s BNPL business models, the former has a clear advantage during the ongoing macroeconomic landscape. Additionally, Upstart profitability prospects are much more attractive, providing investors with a much wider margin of safety against Affirm’s money-losing operations. This, combined with the fact that Upstart is trading at a relatively cheap valuation, leads me to the conclusion that Upstart has a significantly higher chance of repairing investors’ recent losses.","news_type":1,"symbols_score_info":{"AFRM":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":3267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008433356,"gmtCreate":1641510554911,"gmtModify":1676533622160,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Up And Down","listText":"Up And Down","text":"Up And Down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008433356","repostId":"1137932427","repostType":4,"isVote":1,"tweetType":1,"viewCount":996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081952501,"gmtCreate":1650185506346,"gmtModify":1676534665579,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/U11.SI\">$UNITED OVERSEAS BANK LIMITED(U11.SI)$</a>Constantly growing&nbsp;","listText":"<a href=\"https://ttm.financial/S/U11.SI\">$UNITED OVERSEAS BANK LIMITED(U11.SI)$</a>Constantly growing&nbsp;","text":"$UNITED OVERSEAS BANK LIMITED(U11.SI)$Constantly growing","images":[{"img":"https://community-static.tradeup.com/news/4f7bf6de7196a630be684eb64495b2bc","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081952501","isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9002451911,"gmtCreate":1642079273764,"gmtModify":1676533678536,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Good job","listText":"Good job","text":"Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002451911","repostId":"1109527672","repostType":4,"repost":{"id":"1109527672","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642076396,"share":"https://ttm.financial/m/news/1109527672?lang=en_US&edition=fundamental","pubTime":"2022-01-13 20:19","market":"us","language":"en","title":"AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US","url":"https://stock-news.laohu8.com/highlight/detail?id=1109527672","media":"Benzinga","summary":"AstraZeneca Plc said the U.S. government has agreed to purchase an additional 500,000 doses of its a","content":"<html><head></head><body><p><b>AstraZeneca Plc</b> said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.</p><ul><li>The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.</li><li>The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.</li><li>In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.</li><li>The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.</li><li>The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.</li><li><b>Price Action:</b> AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-13 20:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>AstraZeneca Plc</b> said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.</p><ul><li>The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.</li><li>The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.</li><li>In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.</li><li>The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.</li><li>The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.</li><li><b>Price Action:</b> AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109527672","content_text":"AstraZeneca Plc said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-19.The Company said the delivery of the doses was expected in Q1 of 2022, and more details about the deal would be announced in the coming weeks.The additional doses will add to the previous purchase of 700,000 doses of the antibody therapy.In December, the antibody showed it retained neutralizing activity against the highly transmissible Omicron coronavirus variant in a lab study.The FDA last month authorized Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.The Company said it is the only antibody therapy authorized in the United States to prevent COVID-19 symptoms before virus exposure.Price Action: AZN shares are -0.2% at $58.39 during the premarket session on the last check Thursday.","news_type":1,"symbols_score_info":{"AZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008845352,"gmtCreate":1641426033824,"gmtModify":1676533613147,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"Amazing&nbsp;","listText":"Amazing&nbsp;","text":"Amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008845352","repostId":"1192162576","repostType":4,"repost":{"id":"1192162576","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641393700,"share":"https://ttm.financial/m/news/1192162576?lang=en_US&edition=fundamental","pubTime":"2022-01-05 22:41","market":"us","language":"en","title":"Sony Jumped over 3% in Morning Trading as It Announced New Electric-Vehicle unit at CES 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1192162576","media":"Tiger Newspress","summary":"Sony jumped over 3% in morning trading as it announced new electric-vehicle unit at CES 2022.Sony Gr","content":"<html><head></head><body><p>Sony jumped over 3% in morning trading as it announced new electric-vehicle unit at CES 2022.<img src=\"https://static.tigerbbs.com/a1ade3ba83955109b1fc2fbd3aaac022\" tg-width=\"769\" tg-height=\"565\" width=\"100%\" height=\"auto\"/>Sony Group will establish a new company for electric vehicles this spring, its chairman said, becoming the latest tech company to beef up its ambitions in the fast-growing market.</p><p>It also announced a new electric-vehicle unit, Sony Mobility Inc., and unveiled a prototype of its latest concept car Tuesday night at CES 2022.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sony Jumped over 3% in Morning Trading as It Announced New Electric-Vehicle unit at CES 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSony Jumped over 3% in Morning Trading as It Announced New Electric-Vehicle unit at CES 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-05 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Sony jumped over 3% in morning trading as it announced new electric-vehicle unit at CES 2022.<img src=\"https://static.tigerbbs.com/a1ade3ba83955109b1fc2fbd3aaac022\" tg-width=\"769\" tg-height=\"565\" width=\"100%\" height=\"auto\"/>Sony Group will establish a new company for electric vehicles this spring, its chairman said, becoming the latest tech company to beef up its ambitions in the fast-growing market.</p><p>It also announced a new electric-vehicle unit, Sony Mobility Inc., and unveiled a prototype of its latest concept car Tuesday night at CES 2022.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SONY":"索尼"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192162576","content_text":"Sony jumped over 3% in morning trading as it announced new electric-vehicle unit at CES 2022.Sony Group will establish a new company for electric vehicles this spring, its chairman said, becoming the latest tech company to beef up its ambitions in the fast-growing market.It also announced a new electric-vehicle unit, Sony Mobility Inc., and unveiled a prototype of its latest concept car Tuesday night at CES 2022.","news_type":1,"symbols_score_info":{"SONY":0.9}},"isVote":1,"tweetType":1,"viewCount":700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9082857202,"gmtCreate":1650552691704,"gmtModify":1676534750569,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/Z74.SI\">$SINGTEL(Z74.SI)$</a>growing up","listText":"<a href=\"https://ttm.financial/S/Z74.SI\">$SINGTEL(Z74.SI)$</a>growing up","text":"$SINGTEL(Z74.SI)$growing up","images":[{"img":"https://community-static.tradeup.com/news/7f6801acc4a43057043daef49fbf2c06","width":"750","height":"1617"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9082857202","isVote":1,"tweetType":1,"viewCount":976,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9086531245,"gmtCreate":1650468228080,"gmtModify":1676534731255,"author":{"id":"4102833749708340","authorId":"4102833749708340","name":"See C","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4102833749708340","idStr":"4102833749708340"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>[Smile]&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>[Smile]&nbsp;","text":"$Tesla Motors(TSLA)$[Smile]","images":[{"img":"https://community-static.tradeup.com/news/ba6796632a0cf47e20f88403e6a2d7ca","width":"750","height":"2059"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9086531245","isVote":1,"tweetType":1,"viewCount":942,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}